Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Royalty Pharma Company

RPRX
GB00BMVP7Y09
A2P62D

Price

27.87
Today +/-
-0.14
Today %
-0.54 %
P

Royalty Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Royalty Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Royalty Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Royalty Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Royalty Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Royalty Pharma Stock Price History

DateRoyalty Pharma Price
10/14/202427.87 undefined
10/11/202428.02 undefined
10/10/202427.49 undefined
10/9/202427.58 undefined
10/8/202427.36 undefined
10/7/202427.57 undefined
10/4/202427.75 undefined
10/3/202427.75 undefined
10/2/202428.24 undefined
10/1/202428.38 undefined
9/30/202428.29 undefined
9/27/202428.21 undefined
9/26/202428.19 undefined
9/25/202427.65 undefined
9/24/202427.71 undefined
9/23/202427.71 undefined
9/20/202427.54 undefined
9/19/202427.99 undefined
9/18/202428.21 undefined
9/17/202428.24 undefined
9/16/202428.26 undefined

Royalty Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Royalty Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Royalty Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Royalty Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Royalty Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Royalty Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Royalty Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Royalty Pharma’s growth potential.

Royalty Pharma Revenue, EBIT and net profit per share

DateRoyalty Pharma RevenueRoyalty Pharma EBITRoyalty Pharma Net Income
2029e3.32 B undefined0 undefined4.19 B undefined
2028e3.09 B undefined2.62 B undefined4.07 B undefined
2027e2.95 B undefined2.51 B undefined3.58 B undefined
2026e3.24 B undefined2.42 B undefined2.93 B undefined
2025e2.92 B undefined2.26 B undefined2.65 B undefined
2024e2.69 B undefined2.06 B undefined2.38 B undefined
20232.35 B undefined1.49 B undefined1.13 B undefined
20222.24 B undefined922.9 M undefined42.8 M undefined
20212.29 B undefined1.43 B undefined619.7 M undefined
20202.12 B undefined1.66 B undefined495.2 M undefined
20191.81 B undefined2.62 B undefined2.35 B undefined
20181.79 B undefined1.36 B undefined1.38 B undefined
20171.6 B undefined939.7 M undefined1.21 B undefined

Royalty Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
1.61.791.812.122.292.242.352.692.923.242.953.093.32
-12.341.1116.987.87-2.275.2314.198.6710.85-9.055.037.34
-------------
0000000000000
0.941.362.621.661.430.921.492.062.262.422.512.620
58.8076.03144.6078.2362.4741.2263.3876.6077.3474.6885.3784.80-
1.211.382.350.50.620.041.132.382.652.933.584.074.19
-13.8070.52-78.9225.05-93.212,600.00109.7011.2710.5822.2513.703.12
-------------
-------------
595.4595.4595.4375.5414.8438602.9000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Royalty Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Royalty Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
201820192020202120222023
           
2.390.792.652.82.431.23
363433531714.24
16356152022.41
000000
24097913.8
2.610.832.72.882.561.27
000000
8.6711.4813.2714.6314.2315.1
000000
765229600
000000
1988294306.52
8.7611.6213.3214.6414.2615.11
11.3712.4516.0217.5216.8216.38
           
3.283.280000
002.873.513.674.01
1.222.831.922.261.972.52
00000-0
-102341600
4.496.114.825.785.636.53
411116815.17
00152585451.68
2944014510810794.53
000000
281282009980
0.580.330.310.171.170.16
6.245.965.827.16.126.14
000000
0190030.9
6.245.985.827.16.126.14
6.826.316.137.277.296.3
11.3112.4210.9513.0512.9212.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Royalty Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Royalty Pharma's financial health and stability.

Assets

Royalty Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Royalty Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Royalty Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Royalty Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
0000000
0000000
0000000
-142-329-94-11-213-11338
0005222
-235-267-255-103-130-170-169
0000000
1.421.621.672.032.022.142.99
-2,290-269-1,721-2,182-2,191-1,741-2,115
-1,587303-2,116-2,759-1,870-1,029-2,072
703573-394-57732171242
0000000
0.91-0.29-0.290.681.270-1
0001.9100-0.3
-0.12-1.38-1.191.490.39-0.94-2.15
-1,030.00-1,085.00-897.00-989.00-602.00-611.00-485.00
000-112-285-333-358
1.52.760.382.912.892.61.88
-872.41,348.7-54.1-147.6-174402.4872.28
0000000

Royalty Pharma stock margins

The Royalty Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Royalty Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Royalty Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Royalty Pharma's sales revenue. A higher gross margin percentage indicates that the Royalty Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Royalty Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Royalty Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Royalty Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Royalty Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Royalty Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Royalty Pharma Margin History

Royalty Pharma Gross marginRoyalty Pharma Profit marginRoyalty Pharma EBIT marginRoyalty Pharma Profit margin
2029e0 %0 %126.35 %
2028e0 %84.8 %131.52 %
2027e0 %85.34 %121.44 %
2026e0 %74.68 %90.38 %
2025e0 %77.31 %90.57 %
2024e0 %76.6 %88.47 %
20230 %63.37 %48.2 %
20220 %41.25 %1.91 %
20210 %62.49 %27.07 %
20200 %78.24 %23.33 %
20190 %144.58 %129.44 %
20180 %76.02 %76.76 %
20170 %58.81 %75.72 %

Royalty Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Royalty Pharma earnings per share therefore indicates how much revenue Royalty Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Royalty Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Royalty Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Royalty Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Royalty Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Royalty Pharma Revenue, EBIT and net profit per share

DateRoyalty Pharma Sales per ShareRoyalty Pharma EBIT per shareRoyalty Pharma Earnings per Share
2029e5.59 undefined0 undefined7.07 undefined
2028e5.21 undefined0 undefined6.85 undefined
2027e4.96 undefined0 undefined6.03 undefined
2026e5.46 undefined0 undefined4.93 undefined
2025e4.92 undefined0 undefined4.46 undefined
2024e4.53 undefined0 undefined4.01 undefined
20233.91 undefined2.47 undefined1.88 undefined
20225.11 undefined2.11 undefined0.1 undefined
20215.52 undefined3.45 undefined1.49 undefined
20205.65 undefined4.42 undefined1.32 undefined
20193.05 undefined4.41 undefined3.94 undefined
20183.01 undefined2.29 undefined2.31 undefined
20172.68 undefined1.58 undefined2.03 undefined

Royalty Pharma business model

Royalty Pharma PLC is a US-based company specializing in investments in biopharmaceutical companies and their products. The company was founded in 1996 by Pablo Legorreta and is headquartered in New York City. It has subsidiaries in Bermuda, Ireland, Luxembourg, and Switzerland. The business model of Royalty Pharma involves providing financial resources to manufacturers of biopharmaceuticals in exchange for a share in the licenses and sales of their products. This allows Royalty Pharma to participate in the development and commercial exploitation of medications without bearing the risk of developing active substances or obtaining approvals. In recent years, Royalty Pharma has invested in a variety of companies to benefit from their commercial success. Examples of companies they work with include Biomarin Pharmaceuticals, Vertex, Teva Pharmaceutical Industries, and General Electric. Royalty Pharma now has a portfolio of over 45 investments in products from companies such as AbbVie, Gilead, Roche, and Amgen. The range of products includes cancer therapies and vaccines, used for both rare diseases and broader applications. One of the most well-known products in Royalty Pharma's portfolio is the cancer drug Kadcyla from Roche. This medication is used in the treatment of breast cancer and has been successful in slowing tumor growth. Another example is the commercial success of the hepatitis C medication Harvoni from Gilead, which improves the quality of life for affected patients and saves lives. Royalty Pharma also has a financing division that focuses on the purchase of existing or future license fees. This division offers credit agreements for biopharmaceutical companies and serves as a good financing alternative for small and medium-sized enterprises. Overall, Royalty Pharma has a successful track record in investing in the biopharmaceutical industry. The model allows the company to benefit from innovative products and their commercial exploitation without taking on the risk of drug development. This allows the company to continue offering attractive returns to its investors. Royalty Pharma is one of the most popular companies on Eulerpool.com.

Royalty Pharma Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Royalty Pharma Revenue by Segment

Segmente2023202220212020
Income from financial royalty assets2.2 B USD2.13 B USD2.07 B USD-
Financial Royalty Assets---1.96 B USD
Other royalty income155.97 M USD74.64 M USD53.13 M USD-
Revenue from intangible royalty assets835,000 USD37.48 M USD171.25 M USD-
Intangible Royalty Assets---143.38 M USD
Royalty Income, Other---19 M USD

Royalty Pharma SWOT Analysis

Strengths

Royalty Pharma PLC is a leading company in the pharmaceutical industry, with a strong track record of successful investments and acquisitions. The company has a diverse portfolio of royalty interests in various therapeutic areas, providing a stable and reliable source of revenue. Royalty Pharma has established strong relationships with top pharmaceutical companies, enabling them to access a wide range of potential investment opportunities. The company's experienced management team has deep industry knowledge and expertise, ensuring effective decision-making and strategic planning.

Weaknesses

Royalty Pharma's business model is heavily dependent on the success of the pharmaceutical products it invests in. The company faces the risk of failing to identify profitable investment opportunities or realizing lower-than-expected returns on its investments. Royalty Pharma also operates in a highly regulated industry, which may create challenges in terms of compliance and changes in government policies. The company's revenue streams are subject to fluctuations based on the performance and sales of the underlying pharmaceutical products.

Opportunities

The pharmaceutical industry continues to evolve, presenting new opportunities for Royalty Pharma to invest in innovative therapies and treatments. Increased global healthcare spending and advancements in medical technology create a favorable environment for growth in the sector. Royalty Pharma can explore partnerships or collaborations with research institutions and biotech companies to access early-stage investment opportunities. Expansion into emerging markets or therapeutic areas can provide additional avenues for revenue and diversification.

Threats

Royalty Pharma faces intense competition from other investment firms and pharmaceutical companies seeking royalty interests. Rapid changes in the healthcare landscape and regulatory environment can impact the profitability and viability of Royalty Pharma's investments. There is inherent uncertainty and risks associated with the success or failure of clinical trials and regulatory approvals for the pharmaceutical products in which the company holds interests. Economic downturns or market volatility can affect the availability of capital for Royalty Pharma's investment activities.

Royalty Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Royalty Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Royalty Pharma shares outstanding

The number of shares was Royalty Pharma in 2023 — This indicates how many shares 602.9 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Royalty Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Royalty Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Royalty Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Royalty Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Royalty Pharma dividend history and estimates

In 2023, Royalty Pharma paid a dividend amounting to 0.8 USD. Dividend means that Royalty Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Royalty Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Royalty Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Royalty Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Royalty Pharma Dividend History

DateRoyalty Pharma Dividend
2029e0.78 undefined
2028e0.78 undefined
2027e0.78 undefined
2026e0.78 undefined
2025e0.78 undefined
2024e0.78 undefined
20230.8 undefined
20220.76 undefined
20210.68 undefined
20200.3 undefined

Royalty Pharma dividend payout ratio

In 2023, Royalty Pharma had a payout ratio of 276.12%. The payout ratio indicates the percentage of the company's profits that Royalty Pharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Royalty Pharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Royalty Pharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Royalty Pharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Royalty Pharma Payout Ratio History

DateRoyalty Pharma Payout ratio
2029e391.86 %
2028e410.29 %
2027e397.86 %
2026e367.43 %
2025e465.57 %
2024e360.59 %
2023276.12 %
2022760 %
202145.64 %
202022.73 %
2019276.12 %
2018276.12 %
2017276.12 %
Unfortunately, there are currently no price targets and forecasts available for Royalty Pharma.

Royalty Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.98 0.96  (-2.47 %)2024 Q2
3/31/20241 0.98  (-2.16 %)2024 Q1
12/31/20231.03 1.15  (11.63 %)2023 Q4
9/30/20230.77 0.79  (2.45 %)2023 Q3
6/30/20230.82 0.84  (1.92 %)2023 Q2
3/31/20231.3 1.6  (23.19 %)2023 Q1
12/31/20221.5 1.56  (3.87 %)2022 Q4
9/30/20220.73 0.72  (-1.45 %)2022 Q3
6/30/20220.8 0.79  (-0.87 %)2022 Q2
3/31/20220.75 0.6  (-19.6 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Royalty Pharma stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

20

👫 Social

92

🏛️ Governance

62

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees18
Share of Asian management—
Percentage of Hispanic/Latino employees9
Hispano/Latino Management share—
Percentage of Black employees3
Black Management Share—
Percentage of white employees67
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Royalty Pharma shareholders

%
Name
Stocks
Change
Date
6.81725 % Morgan Stanley Investment Management Inc. (US)40,457,646-2,043,63512/31/2023
6.36811 % The Vanguard Group, Inc.37,792,161-1,476,87612/31/2023
5.07512 % Fidelity Management & Research Company LLC30,118,7971,264,94112/31/2023
2.96405 % Baillie Gifford & Co.17,590,450-650,83412/31/2023
2.58751 % BlackRock Institutional Trust Company, N.A.15,355,821875,69312/31/2023
1.90789 % Giuliani (Mario Germano)11,322,592-44,098,2384/11/2023
1.83617 % Adage Capital Management, L.P.10,896,9311,056,93112/31/2023
1.69976 % Viking Global Investors LP10,087,417623,21612/31/2023
1.49522 % State Street Global Advisors (US)8,873,550447,93412/31/2023
1.15750 % Swedbank Robur Fonder AB6,869,300932,3002/29/2024
1
2
3
4
5
...
10

Royalty Pharma Executives and Management Board

Mr. Pablo Legorreta59
Royalty Pharma Chairman of the Board, Chief Executive Officer
Compensation 49.51 M
Mr. Christopher Hite56
Royalty Pharma Vice Chairman, Executive Vice President
Compensation 4.35 M
Mr. Terrance Coyne41
Royalty Pharma Chief Financial Officer, Executive Vice President
Compensation 4.35 M
Mr. George Lloyd63
Royalty Pharma Executive Vice President - Investments and Chief Legal Officer (since 2022)
Compensation 4.35 M
Dr. Marshall Urist47
Royalty Pharma Executive Vice President - Research and Investments
Compensation 4.35 M
1
2
3

Most common questions regarding Royalty Pharma

What values and corporate philosophy does Royalty Pharma represent?

Royalty Pharma PLC represents values of innovation, integrity, and long-term growth. As a global leader in the pharmaceutical industry, the company is committed to providing value to patients, healthcare providers, and investors. With a focus on acquiring royalty interests in established biopharmaceutical products, Royalty Pharma aims to deliver a consistent and attractive return on investment. The company's corporate philosophy centers around ethical business practices, strategic partnerships, and driving advancements in medical treatments. By leveraging its expertise and extensive network, Royalty Pharma strives to provide reliable and sustainable investment opportunities in the healthcare sector.

In which countries and regions is Royalty Pharma primarily present?

Royalty Pharma PLC is primarily present in various countries and regions globally. With a focus on the biopharmaceutical sector, Royalty Pharma operates across multiple geographies, including the United States, Europe, and Asia. The company actively engages in acquiring and managing intellectual property rights related to healthcare innovations, collaborating with biotechnology and pharmaceutical companies worldwide. Through its presence in these regions, Royalty Pharma PLC aims to positively impact patients' lives by investing in the development of new therapies and treatments.

What significant milestones has the company Royalty Pharma achieved?

Royalty Pharma PLC has achieved numerous significant milestones since its establishment. The company, founded in 1996, is a leading investor in biopharmaceutical royalties. Over the years, Royalty Pharma has successfully built a diverse portfolio of royalty interests. As of now, the company has invested in over 100 commercial products, including some of the top-selling drugs in the world. With a focus on long-term value creation, Royalty Pharma has consistently delivered attractive returns to its shareholders. Its expertise in evaluating, structuring, and executing royalty transactions has made it a trusted partner for biopharmaceutical companies. The company's commitment to innovation and strategic investments continues to drive its success.

What is the history and background of the company Royalty Pharma?

Royalty Pharma PLC is a renowned pharmaceutical investment company with a rich history and background. Founded in 1996, the company specialized in acquiring and managing royalty interests in various therapeutic products. It has successfully forged partnerships with leading pharmaceutical companies to generate revenues from the commercial success of licensed drugs. With a strong focus on healthcare innovation, Royalty Pharma PLC has played a significant role in supporting the development and advancement of life-saving treatments. Over the years, the company has established a solid reputation for its expertise in the pharmaceutical sector and its commitment to delivering value for shareholders.

Who are the main competitors of Royalty Pharma in the market?

The main competitors of Royalty Pharma PLC in the market include companies such as Johnson & Johnson, Novartis, Merck & Co., Pfizer, and GlaxoSmithKline.

In which industries is Royalty Pharma primarily active?

Royalty Pharma PLC is primarily active in the healthcare and pharmaceutical industries. With a focus on intellectual property assets related to biopharmaceutical products, the company acquires and manages a diverse portfolio of royalties. Royalty Pharma PLC partners with leading biopharmaceutical companies, investing in innovative therapies for various medical conditions. As a prominent player in the industry, Royalty Pharma PLC plays a significant role in supporting the development of life-saving drugs and breakthrough treatments.

What is the business model of Royalty Pharma?

The business model of Royalty Pharma PLC revolves around investing in pharmaceutical royalties. As a leading buyer of biopharmaceutical royalties, the company acquires the rights to future royalty payments from innovative drugs. Royalty Pharma provides upfront financing to biopharmaceutical companies in exchange for a portion of their future product revenues. By doing so, Royalty Pharma helps these companies access immediate capital, allowing them to invest in research, development, and commercialization of new treatments. With a diversification strategy, Royalty Pharma aims to generate attractive risk-adjusted returns by focusing on a broad portfolio of high-quality pharmaceutical assets. This model positions Royalty Pharma as a formidable player in the global healthcare sector.

What is the P/E ratio of Royalty Pharma 2024?

The Royalty Pharma P/E ratio is 7.07.

What is the P/S ratio of Royalty Pharma 2024?

The Royalty Pharma P/S ratio is 6.25.

What is the Quality Investing of Royalty Pharma?

The Quality Investing for Royalty Pharma is 3/10.

What is the revenue of Royalty Pharma 2024?

The expected Royalty Pharma revenue is 2.69 B USD.

How high is the profit of Royalty Pharma 2024?

The expected Royalty Pharma profit is 2.38 B USD.

What is the business model of Royalty Pharma

Royalty Pharma PLC is a leading investor in biotech and pharmaceutical companies. The company's business model is based on acquiring license fees for successful patents from pharmaceutical companies. The company has a large catalog of investments in various sectors of the healthcare industry, including oncology, neurology, diabetes, autoimmune diseases, and many others. Royalty Pharma specializes in acquiring a variety of license fees for pharmaceutical products to create a secure and steady source of income for end consumers. The company works closely with biotech companies and innovators to find the best investment and collaboration opportunities. As part of its business model, Royalty Pharma offers a variety of financial products specifically tailored to the needs of biotech and pharmaceutical companies, including mezzanine capital, high-yield bonds, and lending. In addition to financial products, Royalty Pharma also offers its comprehensive expertise in the industry. Thanks to its extensive experience, the company has access to a network of professionals that allows its partners to maximize their growth potential. This expertise includes constant monitoring of industry developments, evaluation of potential target companies, and conducting thorough due diligence. The heart of Royalty Pharma's business, however, lies in discovering investment opportunities in the healthcare industry. These opportunities can range from acquiring patented drugs to investing in the development of new therapeutics. The company always strives to achieve a balanced risk-reward ratio in order to generate the greatest value for all stakeholders. In summary, Royalty Pharma's business model is focused on maximizing the value of patented therapeutics and technologies in the biotech and pharmaceutical industry. By leveraging license fees, the company acquires steady cash flows that can be invested in further growth opportunities. Therefore, Royalty Pharma has become an indispensable partner in the industry for many companies.

What is the Royalty Pharma dividend?

Royalty Pharma pays a dividend of 0.76 USD distributed over 4 payouts per year.

How often does Royalty Pharma pay dividends?

Royalty Pharma pays out a dividend 4 times a year.

What is the Royalty Pharma ISIN?

The ISIN of Royalty Pharma is GB00BMVP7Y09.

What is the Royalty Pharma WKN?

The WKN of Royalty Pharma is A2P62D.

What is the Royalty Pharma ticker?

The ticker of Royalty Pharma is RPRX.

How much dividend does Royalty Pharma pay?

Over the past 12 months, Royalty Pharma paid a dividend of 0.8 USD . This corresponds to a dividend yield of about 2.87 %. For the coming 12 months, Royalty Pharma is expected to pay a dividend of 0.78 USD.

What is the dividend yield of Royalty Pharma?

The current dividend yield of Royalty Pharma is 2.87 %.

When does Royalty Pharma pay dividends?

Royalty Pharma pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Royalty Pharma?

Royalty Pharma paid dividends every year for the past 10 years.

What is the dividend of Royalty Pharma?

For the upcoming 12 months, dividends amounting to 0.78 USD are expected. This corresponds to a dividend yield of 2.79 %.

In which sector is Royalty Pharma located?

Royalty Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Royalty Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Royalty Pharma from 9/13/2024 amounting to 0.21 USD, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Royalty Pharma pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Royalty Pharma in the year 2023?

In the year 2023, Royalty Pharma distributed 0.76 USD as dividends.

In which currency does Royalty Pharma pay out the dividend?

The dividends of Royalty Pharma are distributed in USD.

All fundamentals about Royalty Pharma

Our stock analysis for Royalty Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Royalty Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.